[go: up one dir, main page]

NO951061L - Antibody conjugates with improved properties - Google Patents

Antibody conjugates with improved properties

Info

Publication number
NO951061L
NO951061L NO951061A NO951061A NO951061L NO 951061 L NO951061 L NO 951061L NO 951061 A NO951061 A NO 951061A NO 951061 A NO951061 A NO 951061A NO 951061 L NO951061 L NO 951061L
Authority
NO
Norway
Prior art keywords
improved properties
antibody conjugates
conjugate
mammal
human
Prior art date
Application number
NO951061A
Other languages
Norwegian (no)
Other versions
NO951061D0 (en
Inventor
Brendan Murray
Terence O'reilly
Gerd Pluschke
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO951061D0 publication Critical patent/NO951061D0/en
Publication of NO951061L publication Critical patent/NO951061L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Det blir beskrevet et oppløselig konjugat hvor et bæreprotein er kovalent bundet til et monoklonalt antistoff, et farmasøytisk preparat omfattende et slikt konjugat og en fremgangmsåte for fremstillingen derav. Et konjugat Ifølge oppfinnelsen er nyttig f.eks. for aktiv immunoterapi av et pattedyr, spesielt et menneske.A soluble conjugate is described in which a carrier protein is covalently linked to a monoclonal antibody, a pharmaceutical composition comprising such a conjugate and a method of making the same. A conjugate according to the invention is useful e.g. for active immunotherapy of a mammal, especially a human.

NO951061A 1994-03-21 1995-03-20 Antibody conjugates with improved properties NO951061L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94810173 1994-03-21

Publications (2)

Publication Number Publication Date
NO951061D0 NO951061D0 (en) 1995-03-20
NO951061L true NO951061L (en) 1995-09-22

Family

ID=8218230

Family Applications (1)

Application Number Title Priority Date Filing Date
NO951061A NO951061L (en) 1994-03-21 1995-03-20 Antibody conjugates with improved properties

Country Status (11)

Country Link
JP (1) JPH0820545A (en)
KR (1) KR950031111A (en)
AU (1) AU1481795A (en)
CA (1) CA2144936A1 (en)
FI (1) FI951276L (en)
HU (1) HUT71776A (en)
IL (1) IL113022A (en)
NO (1) NO951061L (en)
NZ (1) NZ270734A (en)
RU (1) RU95104325A (en)
ZA (1) ZA952269B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2865737B1 (en) * 2004-02-03 2006-03-31 Anteis Sa BIOCOMPATIBLE RETICLE GEL

Also Published As

Publication number Publication date
AU1481795A (en) 1995-09-28
JPH0820545A (en) 1996-01-23
IL113022A0 (en) 1995-06-29
HUT71776A (en) 1996-01-29
KR950031111A (en) 1995-12-18
ZA952269B (en) 1995-09-21
FI951276A0 (en) 1995-03-17
FI951276A7 (en) 1995-09-22
FI951276L (en) 1995-09-22
IL113022A (en) 2000-02-29
HU9500586D0 (en) 1995-04-28
NZ270734A (en) 1997-05-26
RU95104325A (en) 1996-12-27
CA2144936A1 (en) 1995-09-22
NO951061D0 (en) 1995-03-20

Similar Documents

Publication Publication Date Title
PT1135498E (en) Antibody variants with higher binding affinity compared to parent antibodies
DK499086A (en) CONJUGATES OF THE TRICHOTHECEN AND USE OF SAME AS THERAPEUTIC SUBSTANCE
CO4850562A1 (en) PROCESS TO PRODUCE A CONCENTRATED PREPARATION OF ANTIBODIES
EP4378958A3 (en) High-affinity anti-mertk antibodies and uses thereof
EP0724456A4 (en) ANTIBODIES DIRECTED AGAINST CD40
ATE383430T1 (en) RECOMBINANT ANTIBODIES AND IMMUNE CONJUGATES TARGETED AT CD22-BEARING CELLS AND TUMORS
PL248202A1 (en) Process for preparing conjugate with chain b of toxin and method of manufacture of cytotoxic composition
ATE267610T1 (en) GLYCOSYLATED IGG ANTIBODIES
EP0683234A4 (en) ANTIBODY AGAINST -g(b)-AMYLOID OR DERIVATIVE THEREOF AND USE THEREOF.
AU563356B2 (en) Conjugate of enzyme and antibody
AU628948B2 (en) Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof
DK0969873T3 (en) Multiple carbohydrate-containing glycopeptide antigens, vaccine containing them, and use thereof
PT97423A (en) METHOD FOR PREPARING PHARMACEUTICAL COMPOSITIONS CONTAINING ANTIBODIES CONJUGATES FOR THE TREATMENT OF NEOPLASMS
EP0350690A3 (en) Neutralisation of the in vitro and in vivo toxic properties of tnf-alpha by monoclonal antibodies and by fragments derived therefrom
IS4922A (en) Polypeptides capable of forming antigen-specific forms of specificity for the resus D antigen, the DNA that represents them, and the method of preparing a saline and its use
DE69328779D1 (en) BENZODIAZEPINE DERIVATIVES AND THEIR CONJUGATES WITH PROTEINS AND POLYPEPTIDES
NO951061L (en) Antibody conjugates with improved properties
ES2082132T3 (en) COMPOSITION CONTAINING AT LEAST TWO DIFFERENT ANTIBODIES OR FRAGMENTS OF THEM.
DE69611037D1 (en) METHADONE DERIVATIVES AND PROTEIN AND POLYPEPTIDE METHADONE CONJUGATES AND MARKED COMPOUNDS
Fodstad et al. New indirect approach to the therapeutic use of immunotoxins
DK0513565T3 (en) Monoclonal antibodies against the plasmin-antiplasmin complex, method for their preparation and their use
IL139571A0 (en) A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same
AU3637195A (en) Broadly reactive opsonic antibodies reactive with common staphylococcal antigens
DK0889907T3 (en) Monoclonal antibodies that bind human growth hormone (hGH)
JPH0469345A (en) Method for removing tumorous cell